Neal D. Shore, MD, FACS, discusses unmet needs in nonmetastatic castration-resistant prostate cancer.
Neal D. Shore, MD, FACS, medical director, of the Carolina Urologic Research Center, discusses unmet needs in nonmetastatic castration-resistant prostate cancer (CRPC).
Historically, conventional imaging and bone scans yielded negative findings despite patients having rising prostate-specific antigen (PSA) and below castration-range testosterone levels, says Shore.
Prior research demonstrated that rising PSA correlates with progressive disease by way of bone metastasis, soft tissue lymph node involvement, and visceral metastasis of the lung or liver, Shore says.
Additionally, until the phase 3 ARAMIS trial, there was limited level 1 evidence to suggest which therapies could delay the progression of positive findings on imaging, concludes Shore.